Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 451 - 500 out of 12,111

Document Document Title
WO/2011/051520A1
The present invention relates to novel triterpenic saponins from the saffron (Crocus sativus L.) corm, a composition that comprises said saponins, the use thereof as adjuvant substances in protein vaccines, and also in the production of ...  
WO/2011/052919A3
The present invention relates to alpga-galactosylceramide derivatives, to the pharmaceutically acceptable salts thereof, to a method for preparing same, and to a pharmaceutical composition for an immune adjuvant, containing the derivativ...  
WO/2011/048148A2
This invention relates to compounds represented by formula (I) wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes...  
WO/2011/048148A3
This invention relates to compounds represented by formula (I) wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes...  
WO/2011/044751A1
Foliamangiferosides having the general formula (I) are disclosed, wherein R is H or -OCH3. The preparation method of the compounds, pharmaceutical compositions comprising the compounds as the active ingredients, the use of the compounds ...  
WO/2011/046057A1
Provided is a novel and non-natural sialic acid-containing sugar chain compound, which has a binding activity to a viral particle and remains stable even in the presence of sialidase, obtained by using a reaction with the use of a glycos...  
WO/2011/044498A1
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): (Formula (I)), including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2, R3, Z1 and Z2 ...  
WO/2011/044538A1
Compounds having antibacterial activity are disclosed. The compounds have one of the following structures (I) or (II): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2, R3 and Z1 are...  
WO/2011/044498A9
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): (Formula (I)), including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2, R3, Z1 and Z2 ...  
WO/2011/044503A9
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): (Formula (I)), including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2, R3, Z1 and Z2 ...  
WO/2011/044503A1
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): (Formula (I)), including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2, R3, Z1 and Z2 ...  
WO/2011/044501A9
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I) including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q5, R1, R2, R3, Z1 and Z2 are as defin...  
WO/2011/044502A1
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2 and R3 are as defined herein. ...  
WO/2011/044502A9
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2 and R3 are as defined herein. ...  
WO/2011/044501A2
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I) including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q5, R1, R2, R3, Z1 and Z2 are as defin...  
WO/2011/044538A9
Compounds having antibacterial activity are disclosed. The compounds have one of the following structures (I) or (II): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2, R3 and Z1 are...  
WO/2011/044501A3
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I) including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q5, R1, R2, R3, Z1 and Z2 are as defin...  
WO/2011/039107A1
The invention relates to a method for the preparation for a crystalline form of 1-chloro-4-(Β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofura n-3-yloxy)-benzyl]-benzene. In addition the invention relates to a crystalline form obtainable b...  
WO/2011/038356A2
This invention provides novel liver targeting agents and their synthetic methods. A liver targeting agent, with a lysine based nitrilo triacetic acid structure as backbone which acquires multivalency with saccharide groups, to bind with ...  
WO/2011/035518A1
Pyrimidine derivatives and analogs, their pharmaceutically acceptable salts, processes for preparing them, pharmaceutical compositions comprising them, and their use in manufacture of medicaments for treating inflammatory and infectious ...  
WO/2011/029576A1
The present invention relates to a form of crystalline 4'-epidaunorubicin hydrochloride which is stable and readily soluble, and to a process for the production thereof. This process comprises crystallizing 4'-epidaunorubicin hydrochlori...  
WO/2011/025286A2
The present invention relates to lipoteichoic acid-derived glycolipids, and to pharmaceutical, food or cosmetic compositions and vaccine adjuvants comprising same. The lipoteichoic acid-derived glycolipids according to the present invent...  
WO/2011/025286A3
The present invention relates to lipoteichoic acid-derived glycolipids, and to pharmaceutical, food or cosmetic compositions and vaccine adjuvants comprising same. The lipoteichoic acid-derived glycolipids according to the present invent...  
WO/2011/017998A1
Gambogic acid cyclization analogues with formula I, II and III are disclosed, wherein cycles A, B and C are saturated or unsaturated alicyclic, alicyclic heterocyclic, aromatic ring or aromatic heterocyclic groups containing 4-10 members...  
WO/2011/019419A1
Tumors can be selectively targeted via compounds provided herein according to the formula, or a pharmaceutically acceptable salt thereof, wherein RA and RB are as defined herein. Tumors can be imaged or targeted for therapeutic treatment...  
WO/2011/018587A3
The invention relates to FGF receptor-activating N-sulfate oligosaccharides having Formula (I), wherein R1, R4, R6, and R8 are -OSO3- or hydroxyl groups, R2 is an -O-alkyl group or a monosaccharide having Formula (II), R3 is a disacchari...  
WO/2011/018588A3
The invention relates to FGF receptor-activating N-acyl octasaccharides having Formula (I), wherein: R1 is an O-alkyl group optionally replaced by one or more aryl or cycloalkyl groups, R2 is an OSO3- or hydroxyl group, R3 is an alkyl, c...  
WO/2011/016558A1
Disclosed is a method for easily and economically producing a highly pure glucosylceramide-containing material in a large amount from a plant material. A highly pure glucosylceramide can be obtained in a large amount by a method for prod...  
WO/2011/009987A3
Aureolic acid derivatives, the method for preparation thereof and the uses thereof. The present invention provides a bacterial strain that produces compounds belonging to the aureolic acid family, which can be used in the treatment of ca...  
WO/2011/006237A1
Compounds of structural formula (I) useful for the treatment or prophylaxis of viral infection, particularly viral influenza are provided Pharmaceutical preparations thereof and methods for their preparation are also described. The thera...  
WO/2011/003876A1
Herein arc disclosed novel compounds according to Formula (I) and aggregates comprising such compounds. These aggregates arc useful to treat and prevent ocular infections caused by a vims, which virus binds to terminal sialic residues pr...  
WO/2011/000721A1
The present invention finds application in the field of medicine and, in particular, it relates to new compounds for the treatment and/or prevention of HIV; Ebola, Dengue, Hepatitis C, SARS or tuberculosis infections.  
WO/2010/149326A1
The present invention relates to a compound comprising an imine bond as an acid- labile trigger group, the use of such an imine bond as an acid-labile trigger group, a process of cleaving the imine bond in said compound, and a pharmaceut...  
WO/2010/139692A3
The present invention encompasses novel triterpene compounds of general Formula (I) wherein RN1, RN2, R11a, R11b, R4, R17, R19 and R20 are defined as in claim 1, which exhibit an antiviral effect and are therefore suitable for the treatm...  
WO/2010/139692A2
The present invention encompasses novel triterpene compounds of general Formula (I) wherein RN1, RN2, R11a, R11b, R4, R17, R19 and R20 are defined as in claim 1, which exhibit an antiviral effect and are therefore suitable for the treatm...  
WO/2010/138608A1
The present invention provides methods for improving the production of recombinant proteins through the use of pharmacological chaperones for the recombinant proteins. As exemplified by the present invention, the binding of a pharmacolog...  
WO/2010/132768A1
Antibacterial compounds of structure (I) are disclosed, including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R11 and R12 are as defined herein. Methods associated with preparation and use o...  
WO/2010/132759A9
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R1, R2 or R3 are as defined herei...  
WO/2010/132768A9
Antibacterial compounds of structure (I) are disclosed, including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R11 and R12 are as defined herein. Methods associated with preparation and use o...  
WO/2010/132760A1
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R1, R2 and R3 are as defined here...  
WO/2010/132777A3
A method for treating a urinary tract infection in a mammal in need thereof is disclosed, the method comprising administering to the mammal an effective amount of an antibacterial aminoglycoside compound.  
WO/2010/132765A9
Antibacterial compounds of structures (I) and (II) are disclosed, including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R1, R2, R3, R11 are as defined herein. Methods associated with prepara...  
WO/2010/132765A3
Antibacterial compounds of structures (I) and (II) are disclosed, including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R1, R2, R3, R11 are as defined herein. Methods associated with prepara...  
WO/2010/132839A2
The present invention provides new aminoglycoside dosing regimens associated with enhanced microbicidal activity and reduced nephrotoxicity, as well as methods of using these dosing regimens to treat various bacterial infections.  
WO/2010/132759A1
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R1, R2 or R3 are as defined herei...  
WO/2010/132839A9
The present invention provides new aminoglycoside dosing regimens associated with enhanced microbicidal activity and reduced nephrotoxicity, as well as methods of using these dosing regimens to treat various bacterial infections.  
WO/2010/132760A9
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R1, R2 and R3 are as defined here...  
WO/2010/132777A2
A method for treating a urinary tract infection in a mammal in need thereof is disclosed, the method comprising administering to the mammal an effective amount of an antibacterial aminoglycoside compound.  
WO/2010/132765A2
Antibacterial compounds of structures (I) and (II) are disclosed, including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R1, R2, R3, R11 are as defined herein. Methods associated with prepara...  
WO/2010/132839A3
The present invention provides new aminoglycoside dosing regimens associated with enhanced microbicidal activity and reduced nephrotoxicity, as well as methods of using these dosing regimens to treat various bacterial infections.  

Matches 451 - 500 out of 12,111